Lung – NSCLC

Which patient characteristics are most influential on payer management of NSCLC?
Which plans support 1st line use of Tarceva for EGFR + patients?
What impact will the results of the EURTAC trial have on the coverage of single agent Tarceva use?
What are payer perceptions of the use of NSCLC maintenance regimens?
What is the impact on payer management of label expansion to 1st line and maintenance use of certain NSCLC therapies?
Extensive payer feedback to the latest clinical data of Astuprotimut-R, Emepepimut-S (Stimuvax), Crizotinib and MetMAb
Where in the NSCLC treatment algorithm do payers expect these emerging new therapies to fit in?